Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease
Advanced Science · 2026-07 · 13 (39)
DOI: 10.1002/advs.202514830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.04.2026. Verfasst von Shuping Qiao und 11 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Division of Immunology, Medical Scho…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Tryptophan, Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Accumulating evidence suggests that the intestinal microbiota participates in the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD) through microbiota‐host interaction. However, the beneficial role of commensal mycobiota in MASLD progression remains poorly understood. By comparing the gut microbiome differences, we demonstrated that the deficiency of Caspase Recruitment Domain‐containing protein 9 (CARD9), an adaptor protein for a microbiota recognition receptor, exacerbated high‐fat diet (HFD)‐induced MASLD in a gut fungi‐dependent manner. CARD9 deficiency reduced the abundance of Saccharomyces cerevisiae ( S. cerevisiae ), which was a probiotic alleviating MASLD progression. S. cerevisiae promoted a significantly greater abundance of 5‐hydroxyindoleacetic acid (5‐HIAA) in the intestine through Toll‐like receptor 1 (TLR1), which reduced body weight in mice and alleviated MASLD phenotypes via the “gut‐liver” axis. Particularly, 5‐HIAA directly binds to aryl‐hydrocarbon receptor (AhR) and stimulates its nuclear translocation, subsequently inducing fatty acid oxidation via carnitine palmitoyltransferase 1A (CPT1A) and acyl‐CoA oxidase 1 (ACOX1) transactivation. MASLD patients exhibited decreased levels of S. cerevisiae and 5‐HIAA, and S. cerevisiae effectively reduced hepatic steatosis and improved glucose homeostasis in patients with MASLD. In summary, our findings identified a novel pathway of fungi‐ S. cerevisiae stimulating intestinal 5‐HIAA production and indicated that S. cerevisiae and 5‐HIAA might alleviate MASLD progression, highlighting that the mycobiota‐dependent gut‐liver axis was a promising target for the prevention of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Division of Immunology, Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Jiangsu Key Laboratory of Molecular Medicine, Division of Immunology, Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
- Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang, Henan, China.
- Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang, Henan, China.
ORCID-Profile: Tingting Wang
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Qiao, S., Fan, S., Xu, J., Xu, Z., Peng, C., Qu, J., Bing, Z., Zhou, S., Shen, S., Xu, G., Zhao, Y., & Wang, T. (2026). Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease. Advanced Science, 13(39). https://doi.org/10.1002/advs.202514830
Vancouver
Qiao S, Fan S, Xu J, Xu Z, Peng C, Qu J, et al. Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease. Advanced Science. 2026;13(39). doi:10.1002/advs.202514830
BibTeX
@article{Qiao2026,
author = {Qiao, Shuping and Fan, Shuangya and Xu, Juan and Xu, Zhen and Peng, Chen and Qu, Junxing and Bing, Ziqian and Zhou, Shizhen and Shen, Sunan and Xu, Guifang and Zhao, Yue and Wang, Tingting},
title = {Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {39},
doi = {10.1002/advs.202514830}
}
EUVIMED